Other languages Sutro Biopharma, Inc.

Equities

STRO

US8693671021

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
3.83 ^USD	-2.79%		+11.99%	-10.72%

Apr. 30	Sutro Biopharma, Inc. Announces Initiation of Randomized Portion (Part 2) of REFRaME-O1 Trial	CI
Apr. 03	Piper Sandler Trims Price Target on Sutro Biopharma to $11 From $12, Maintains Overweight Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sutro Biopharma, Inc. Announces Initiation of Randomized Portion (Part 2) of REFRaME-O1 Trial	Apr. 30
Ipsen and Sutro Biopharma Announce Exclusive Global Licensing Agreement for an ADC Targeting Solid Tumors	Apr. 02
Winfarm : Atos, Ipsen, Voltalia...les valeurs à suivre aujourd'hui à Paris -	Apr. 02
Ipsen : signature d'un accord exclusif avec Sutro Biopharma	Apr. 02
Ipsen : accord de licence mondiale avec Sutro Biopharma	Apr. 02
Ipsen Signs Licensing Deal for Cancer-targeting Antibody Conjugate with Sutro Biopharma	Apr. 02
Ipsen rachète les droits mondiaux de l'anticancéreux STRO-003 à Sutro Biopharma	Apr. 02
Sutro Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRa-Targeting ADC	Jan. 04
Sutro Biopharma, Inc. Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023	Dec. 11
Vaxcyte, Inc. Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control over Manufacturing and Development of Cell-Free Extract for Its Vaccine Candidates	Nov. 27
Sutro Biopharma, Inc Appoints Jane Chung as President and Chief Operating Officer	Nov. 21
Sutro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Sutro Biopharma Says Endometrial Cancer Therapy Showed 'Encouraging Preliminary Anti-Tumor Activity'	23-10-23
Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Endometrial Cancers At ESMO 2023	23-10-22
Sutro Biopharma, Inc. Appoints Hans Peter Gerber as Chief Scientific Officer	23-09-19
Sutro Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Sutro Biopharma, Blackstone Sign Royalty Financing Agreement	23-06-26
Sutro Biopharma and Blackstone Announces Royalty Financing Collaboration	23-06-26
Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	23-06-14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Sutro Biopharma, Inc.

Equities

STRO

US8693671021

Other languages

Filters